Bringing new therapies to patients typically takes more than a decade and on average costs $2.6B per new drug. Despite this investment, just 12% of clinical trials result in an approved treatment. While increased collaboration and investment across a range of disease fields promises to accelerate the pace and reduce costs, there are many barriers to overcome. 

Philanthropy is a critical tool for improving human health, but donors often lack the expertise and tools needed to navigate intentionally rigorous and often complex research and clinical ecosystems. SPARC advisors, in partnership with high-impact philanthropists, have been working across the scientific ecosystem to identify barriers to progress and pinpoint opportunities to strategically engage in the therapeutic development space.